REFERENCES
1. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477-91.e1.
2. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
3. Yang JD, Mohamed HA, Cvinar JL, et al. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis. Am J Gastroenterol 2016;111:1573-80.
4. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-86.
5. Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol 2017;66:355-362.
6. Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int 2019;13:125-37.
7. Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 2017;152:1954-64.
8. Heimbach JK. Overview of the updated AASLD guidelines for the management of HCC. Gastroenterol Hepatol 2017;13:751-3.
10. Farges O, Malassagne B, Flejou JF, et al. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg 1999;229:210-5.
11. Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010;12:139-46.
12. Buechter M, Thimm J, Baba HA, et al. Liver maximum capacity: a novel test to accurately diagnose different stages of liver fibrosis. Digestion 2019;100:45-54.
13. Buechter M, Kersting S, Gerken G, et al. Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease. Sci Rep 2019;9:13577.
14. Anger F, Klein I, Löb S, et al. Preoperative liver function guiding HCC resection in normal and cirrhotic liver. Visc Med 2021;37:94-101.
15. Blüthner E, Jara M, Shrestha R, et al. The predictive value of future liver remnant function after liver resection for HCC in noncirrhotic and cirrhotic patients. HPB (Oxford) 2019;21:912-22.
16. Stockmann M, Vondran FWR, Fahrner R, et al. Randomized clinical trial comparing liver resection with and without perioperative assessment of liver function. BJS Open 2018;2:301-9.
17. Stockmann M, Lock JF, Riecke B, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009;250:119-25.
18. Barzakova ES, Schulze-Hagen M, Zimmermann M, et al. Monitoring liver function of patients undergoing transarterial chemoembolization (TACE) by a 13C breath test (LiMAx). Cardiovasc Intervent Radiol 2019;42:1702-8.
